Is the CBA (ASX:CBA) share price overvalued?

The Commonwealth Bank of Australia (ASX:CBA) share price is up 18% in November. Is it overvalued now?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Commonwealth Bank of Australia (ASX: CBA) share price has been a very strong performer in November.

Since the start of the month, the CBA share price has climbed an impressive 18% to $81.33.

customer making payment at a cafe using CBA albert

Image Source: Commonwealth Bank

Is it too late to buy CBA shares?

According to a note out of Goldman Sachs, investors might be better off looking at other investment options in the banking sector.

Its analysts have recently retained their sell rating but lifted the price target on the bank's shares slightly to $65.84.

This price target implies potential downside of 19% for its shares over the next 12 months excluding dividends.

Why is Goldman Sachs bearish on the banking giant?

Goldman Sachs has issues over the bank's valuation and the premium its shares trade at in comparison to the rest of the big four.

Following the release of its first quarter update this month, the broker said: "While CBA's balance sheet is strong, with a sector leading capital and provisioning position, CBA's operational performance in 1Q21, particularly as it relates to costs, does not justify the 24% premium it is currently trading on versus peers (versus 15% 15-yr average)."

Which bank does the broker like?

Goldman Sachs' top pick in the sector is National Australia Bank Ltd (ASX: NAB).

It explained: "NAB remains our preferred major bank exposure, based on i) our view that it will deliver better than peer revenue growth, supported by its superior management of the volume/margin trade-off, ii) its investment spend which appears further progressed relative to peers allowing it to be more selective towards where resources are directed, contributing to its broadly flat FY21 cost target (c.0-2%), and iii) when combined, drives our forecast for NAB to deliver top of peer PPOP per share growth over the next three years."

However, it is worth noting that the broker put a price target of $22.96 on NAB's shares last week. But due to its strong share price gain, it is actually now trading above this at $23.60.

I suspect that Goldman Sachs will revisit its recommendation following NAB's annual general meeting in the coming weeks. So stay tuned for that.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy hump day session for the ASX.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Brightstar, EQ Resources, Novonix, and Pro Medicus shares are falling today

These shares are under pressure on hump day. But why?

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why EOS, Humm, New Hope, and Sims shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »